Amgen, GSK To Team Up On Denosumab Commercialization in Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen's big bet on denosumab gets a boost from a Big Pharma partner in Europe, with U.S. rights intact.
You may also be interested in...
Amgen's Prolia Bags Favorable Draft Appraisal From UK Medicines Watchdog
NICE considers denosumab a cost-effective use of NHS resources for second-line osteoporosis use.
Amgen's Prolia Bags Favorable Draft Appraisal From UK Medicines Watchdog
NICE considers denosumab a cost-effective use of NHS resources for second-line osteoporosis use.
Amgen's Prolia Gains First Regulatory Win, With Market Approval in Europe
The European Commission has finally granted a marketing authorization for Amgen's bone loss therapy, Prolia (denosumab), five months after CHMP issued a positive opinion